Efficacy of chemoradiotherapy in pediatric H3K27M-mutant diffuse intrinsic pontine glioma: a study based on single-center and SEER data - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Effectiveness of Chemoradiotherapy for Pediatric H3K27M-Mutant Diffuse Intrinsic Pontine Glioma: Insights from a Single-Center and SEER Analysis

  • By

  • Dandan Wang

  • Xiaohao Liu

  • Juan Wang

  • Boya Zhang

  • Suna Zhai

  • Jiayao Xu

  • Long Wang

  • Yingjuan Zheng

  • Wei Wei

  • Yubing Zhou

  • May 30, 2026

Share

  • 1

    Diffuse intrinsic pontine glioma (DIPG) is a highly aggressive pediatric brain tumor with a poor prognosis and limited treatment options.

  • 2

    Radiotherapy is the standard treatment for DIPG, providing temporary symptom relief but resulting in a median overall survival of only 9-12 months.

  • 3

    The H3K27M mutation is prevalent in DIPG and serves as a critical molecular marker for diagnosis and treatment stratification.

  • 4

    Combining radiotherapy with temozolomide (TMZ) has shown mixed results, with some studies suggesting potential benefits in specific patient subgroups.

  • 5

    This study integrates data from a single-center cohort in China and the SEER database to evaluate treatment efficacy for H3K27M-mutant DIPG.

Original Source(s)

Efficacy of chemoradiotherapy in pediatric H3K27M-mutant diffuse intrinsic pontine glioma: a study based on single-center and SEER data

  • by Dandan Wang, Xiaohao Liu, Juan Wang, Boya Zhang, Suna Zhai, Jiayao Xu, Long Wang, Yingjuan Zheng, Wei Wei, Yubing Zhou

  • May 30, 2026

Related Content

Comparing the utility of FDG PET-CT and contrast-enhanced CT in patients with oesophagogastric adenocarcinoma treated with neoadjuvant chemotherapy

Correction to: HLA Class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC

Posterior fossa ependymoma: a comprehensive review of molecular classification, management guidelines, and clinical outcomes (Part I of ependymomas across compartments)